h1
European SocietyFor Medical Oncology
h2
ESMO Deep Dive: dMMR/MSI-H Colorectal Cancer
h2
Non-Oncogene-Addicted NSCLC Webinar
h2
Patient Guide in Cervical Cancer Now Available Also in Greek
h2
Patient Guide in Pancreatic Cancer Now Available Also in Greek
h2
Talazoparib Plus Enzalutamide Improves rPFS Over Placebo Plus Enzalutamide in First-Line Treatment f
h2
Patient Guide in Non-Small-Cell Lung Cancer Now Available Also in Greek
h2
FDA Approves Olaparib with Abiraterone and Prednisone (or Prednisolone) for BRCA-mutated Metastatic
h2
When your patient is the global population
h2
“Green” prescribing may limit the environmental impact of oncology
h2
Clinical and Biological Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negativ
h2
Adding Capivasertib to Fulvestrant Results in Longer PFS in Patients with HR-positive, HER2-negative
h2
Talazoparib Plus Enzalutamide Improves rPFS Over Placebo Plus Enzalutamide in First-Line Treatment f
h2
FDA Approves Olaparib with Abiraterone and Prednisone (or Prednisolone) for BRCA-mutated Metastatic
h2
Clinical and Biological Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negativ
h2
Adding Capivasertib to Fulvestrant Results in Longer PFS in Patients with HR-positive, HER2-negative
h2
EMA Recommends Granting a Marketing Authorisation for Piflufolastat (18F)
h2
Olaparib Plus Bevacizumab Provides Clinically Meaningful OS Improvement for Newly Diagnosed Patients
h2
FDA Grants Accelerated Approval to Epcoritamab-bysp for Relapsed or Refractory Diffuse Large B-Cell
h2
Significant PFS Benefit in Patients with HR-positive, HER2-negative MBC Who Switched Endocrine Treat
h2
Use of Immune Checkpoint Inhibitors is Safe and Effective in Patients with Cancer and HIV Even in Th
h2
ESMO Launches Living Guidelines to Enhance the Usability of its Clinical Practice Guidelines in Rout
h2
ESMO Breast Cancer Congress 2023
h2
Latest Data Indicate New Care Standard in Advanced/Recurrent Endometrial Cancer: Results from the RU
h2
ESMO Congresses in March: Sarcoma and Rare Cancers Congress and European Lung Cancer Congress
h2
Death Rates from Lung Cancer will Fall Overall in the EU and UK in 2023, but Rise Among Women in Fra
h2
ESMO Targeted Anticancer Therapies Congress 2023
h2
ESMO Gynaecological Cancers Congress 2023
h2
Novel Checklist for Quality of Life to Bring ESMO-MCBS and Clinical Trials to the Next Level
h2
ESMO Immuno-Oncology Congress 2022, 7-9 December, Geneva, Switzerland
h2
Supporting Oncologists at the Point of Care: ESMO Living Guidelines
h2
2023 ESMO Breast Cancer Award Recipient Announced
h2
2023 Heine H. Hansen Award Recipient Announced
h2
2023 TAT Honorary Award Recipient Announced
h2
Nomination Process for the 2023 ESMO Society Awards Now Open
h2
ESMO releases twenty-three new statements on COVID-19 vaccination in people with cancer
h2
ESMO partners with the Lancet Commission on Women and Cancer to advancing gender equity in cancer
h2
ESMO Supports World Cancer Day 2023
h2
Announcing ESMO’s New President and Executive Board
h2
When your patient is the global population
h2
“Green” prescribing may limit the environmental impact of oncology
h2
Early-phase data from targeting HER3 with ADC are encouraging
h2
Extended safety information and PROs data support key trial results in metastatic breast cancer
h2
Does AI hold the future of early cancer detection?
h2
Breast cancer leads the way in ADC therapy
h2
Challenging past dogma in breast cancer research – what's next?
h2
Cemiplimab survival improvements in NSCLC are durable
h2
New insights into targeting KRAS G12C mutations in NSCLC
h2
Axi-Cel OS Benefit Shown For Relapsed/Refractory Large B-Cell Lymphoma
h2
Provide your patients with the best care options.
h2
ESMO Oncology Journals
h2
ESMO Advanced Course on Precision Oncology in Breast Cancer 2023: Barcelona
h2
ESMO Advanced Course on Precision Oncology in Oncogene-Addicted NSCLC: EGFR, ALK, ROS, MET 2023: Bar
h2
ESMO World Congress on Gastrointestinal Cancer 2023
h2
ESMO Course on Medical Oncology for Medical Students Valencia 2023
h2
ESMO Advanced Course on Precision Oncology in Oncogene-Addicted NSCLC: Rare EGFR, KRAS, BRAF, RET 20
h2
ESMO Course on Medical Oncology for Medical Students Naples 2023
h2
ESMO Advanced Course on Cholangiocarcinoma: Where Are We Going? 2023: Barcelona
h2
ESMO Preceptorship on Ovarian Cancer 2023: Lisbon
h2
ESMO Preceptorship on Immuno-Oncology 2023: Zurich
h2
ESMO Preceptorship on Hereditary Cancer Genetics 2023: Paris
h2
ESMO Asia 2023: Brigette Ma on why you should submit your abstract
h2
ESMO Asia 2023: Brigette Ma on programme highlights from this leading Asia-Pacific oncology event
h2
ESMO Asia 2023: Brigette Ma on why young oncologists should attend this leading oncology event
h2
ESMO Asia 2023: Brigette Ma on why you should attend this leading Asia-Pacific oncology event
h2
HER2-low breast cancer: the ESMO Expert Consensus Statements
h2
Claudia Cardone and Andrea Koulouris on why they sat the ESMO Examination
h2
ESMO Asia 2023: Sanjay Popat on the focus of this leading Asia-Pacific oncology event
h2
ESMO Asia 2023: Sanjay Popat on programme highlights from this top Asia-Pacific oncology event
h2
ESMO Asia 2023: Sanjay Popat on why you should attend this leading Asia-Pacific oncology event
h2
ESMO Asia 2023: Sanjay Popat on why young oncologists should attend this top oncology event
h2
ESMO Asia 2023: Andrés Cervantes on the focus of this leading Asia-Pacific oncology event
h2
ESMO Asia 2023: Andrés Cervantes on why young oncologists should attend this top oncology event
h2
Improve your career path
h2
Are you looking for a fellowship not offered by ESMO or would like to post a fellowship?
h2
Thinking of applying for an ESMO Oncology Fellowship?
h3
Congress Scientific Watch
h5
Subscribe to ESMO newsletters